Commentary
A systematic literature review to identify recent epidemiological, biomarker, genetic and clinical evidence that expands our understanding of NAFLD as a metabolic disorder was performed by B. Cariou et al. (Inserm, CNRS, France). It appears that here is a growing body of evidence on the links between NAFLD/NASH pathogenesis and mechanisms of metabolic dysfunction. Given the complex interplay between NAFLD and metabolic dysfunction, for the authors, “there is an urgent need for multidisciplinary collaboration and established protocols for care of patients with NAFLD that are individualised and ideally support reduction of overall metabolic risk as well as treatment for NASH.”
